6. Gastrointestinal

6.1. Clinical Trial
- 6.1.1. Colorectal
- 6.1.2. Rectal
- 6.1.3. Esophageal
- 6.1.4. Gastric
- 6.1.5. Pancreas
- 6.1.6. Other
6.2. Supportive Cancer Care
6.3. Basic Research

6.0 Gastrointestinal
6.1.1.1Colorectal
Study Title	Main Inclusion/Exclusion	Investigational Product	Principal Investigator	Department	Email	Contact number
CodeBreaK 301 (Protocol ID: 20210081) Phase 3 Multicenter, Randomized, Open-label, active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects with Metastatic Colorectal Cancer with KRAS p.G12C Mutation.	Key Inclusion Criteria: 1. Pathologically documented metastatic colorectal adenocarcinoma. 2. Central confirmation of KRAS p.G12C mutation. 3. No prior systemic therapy for metastatic disease except for a maximum of 1 dose of SOC FOLFIRI administered during the screening period.	Experimental: Sotorasib + Panitumumab + FOLFIRI Vs. Control: FOLFIRI ± Bevacizumab-awwb	Dr. Gerry Kwok	Department of Medicine (Medical Oncology)	medicaloncology@hku.hk	2255 1661 2255 4361

Study Title

Main Inclusion/Exclusion

Investigational Product

Principal Investigator

Department

Email

Contact number

Kandlelit-012 (Protocol ID: MK1084-012)

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C- mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer

Key Inclusion Criteria:

4. Pathologically documented metastatic colorectal adenocarcinoma.

5. local confirmation of KRAS p.G12C mutation.

6. No prior systemic therapy for metastatic disease except for a maximum of 1 dose of SOC FOLFIRI administered during the screening period.

Experimental:

MK-1084+Cetuximab + mFOLFOX6

Vs.

Control: mFOLFOX6 ± Bevacizumab

Prof. Thomas Yau

Centre of Cancer Medicine HKU

cancermed@hku.hk

2255 1661 2255 4361

6.1.2Rectal
Study Title		Main Inclusion/Exclusion	Investigational Product		Principal Investigator		Department	Email		Contact number
MEND-IT (Protocol ID: NL74465.100.20): A randomized study of neoadjuvant chemoradiotherapy with or without intensification with the FOLFOXIRI chemo-regimen for high-risk locally advanced rectal cancer.		Key Inclusion Criteria: 1. Histologically confirmed rectal adenocarcinoma (defined as either mid- or low rectal cancer that is located within 12 cm from the anal verge OR below the peritoneal reflection) that is previously untreated. 2. ‘High-risk’ rectal cancer, or rectal cancers that are considered marginally operable where there is a significant risk of ‘positive surgical margin’ (or otherwise known as ‘threatened circumferential margin’) = T3 or T4 tumor with one or more of the following features: · Tumour infiltrating perirectal fat and/or mesorectal fascia and/or vasculature. · Pelvic lymph node involvement. · Absence of distant metastases.	Control: Concurrent neoadjuvant concurrent capecitabine-radiotherapy (Chemo) followed by surgery and post-operative chemotherapy. Vs. Experimental: Neoadjuvant FOLFOXIRI x 4 cycles then concurrent capecitabine-radiotherapy (Chemo), surgery and post-operative chemotherapy.		Dr. Aya El HELALI		Department of Clinical Oncology	ahelali@hku.hk		Kailyn Hui / Dexter Lee 2255 5034
6.1.3 Esophageal
Study Title		Main Inclusion/Exclusion	Investigational Product		Principal Investigator		Department	Email		Contact number
ARTEMIDE Gastric-01 (Protocol ID: D702AC00001) Randomized, Phase III Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First-line Treatment of HER2-positive Gastric Cancer	Key Inclusion Criteria: - locally advanced gastric/GEJ adenocarcinoma - HER2 +ve - CPS >1		Rilvegostomig + Fluoropyrimidine + T-Dxd Vs. Trastuzumab + Chemo + Pembrolizumab	Dr. Gerry Kwok		Department of Medicine (Medical Oncology)		medicaloncology@hku.hk	2255 1661 2255 4361
6.1.5 Pancreas
Study Title	Main Inclusion/ Exclusion		Investigational Product	Principal Investigator		Department		Email	Contact number
(Protocol ID: CA240-0030) A Randomised, phase 2/3 study comparing BMS-986504 Combined with Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion	Key Inclusion Criteria: 1. Centrally confirmed homozygous MTAP deletion detected in tumor tissue 2. Participants must not have received any systemic anticancer treatments in the metastatic setting Key Exclusion Criteria: 1. Prior treatment with a PRMT5 or MAT2A inhibitor.		BMS 986504 (PRMT5 inhibitor) + Gemcitabine + Nab- Paclitaxel Vs. Gemcitabine + Nab- Paclitaxel	Prof. Thomas Yau		Centre of Caner Medicine		cancermed@hku.hk	2255 1661

6.3.1 Basic Research
Study Title	Main Inclusion/Exclusion	Principal Investigator	Department	Email	Contact number
The role of intolerance of uncertainty and negative metacognitive beliefs in fear of cancer recurrence: a longitudinal study.	Key Inclusion Criteria: 1. Are Cantonese- or Mandarin-speakers. 2. Are recently diagnosed with breast cancer or colorectal cancer, without metastatic disease. 3. Have completed the last treatments (surgery or post adjuvant-treatment excluding hormonal and targeted therapy) within the past 18 months. Key Exclusion Criteria: 1. Metastatic cancer.	Dr. Wendy WT Lam	School of Public Health	wwtlam@hku.hk	3917 9878
6.3.2 Basic Research
Silica fragments in human esophagus tissue and its association with esophageal cancer: a case-control study	Local residents in high- and low-incidence areas of China with different dietary cultures and environmental conditions (climate, soil, water).	Dr. Linwei Tian	School of Public Health	linweit@hku.hk	39176351
The glass roots of esophageal cancer in China: needle-shaped diatom frustules in trash fish
6.3.3 Basic Research
Study Title		Principal Investigator	Department	Email	Contact number
Pharmacological effect of Amauroderma rugosum on colon cancer.		Dr. George P.H. Leung	Department of Pharmacology and Pharmacy	gphleung@hku.hk	3917 6861
6.3.4 Basic Research
Nanostring nCounter expression profiling of endogenous transposable elements as a biomarker of prognosis in colorectal cancer		Dr. Jason Wing Hon Wong	School of Biomedical Sciences	jwhwong@hku.hk	Dr. Jason Wing Hon Wong 3917 9187
6.3.5 Basic Research
Development of Photo-targeted Nanocarriers for Esophageal Cancer Therapy.		Dr. W.P. Wang	Department of Pharmacology and Pharmacy	wangwp@hku.hk	3917 9129
6.3.6 Basic Research
Investigation of effects and molecular mechanisms of FGFR2-positive cancer-associate fibroblasts on tumor microenvironment in esophageal squamous cell carcinoma.		Prof. Xin-yuan Guan	School of Biomedical Sciences	xyguan@hku.hk	2255 4352
6.3.7 Basic Research
Gastric Cancer Genomics and Beyond - Moving from Patient Samples to 3D Organoid Cultures for Integrative Genomics Analysis, Drug Sensitivity Assays, Cell Biological Studies and Animal Models.		Prof. Suet Yi Leung	Department of Pathology	suetyi@hku.hk	2255 2664
6.3.8 Basic Research
Targeted degradation of RhoA Y42C mutant protein by Proteolysis-targeting chimera (PROTAC) for gastric cancer therapy.		Dr Clive Yik Sham Chung	School of Biomedical Sciences	cyschung@hku.hk	Dr Clive Yik Sham Chung 3917 9172
6.3.9 Basic Research
Pancreatic Cancer Early Diagnosis using Aptamers		Prof. Julian Alexander Tanner	School of Biomedical Sciences	jatanner@hku.hk	Prof. Julian Alexander Tanner 3917 9472

Swipe to view more →

Cancer Research in HKUMed6. Gastrointestinal

Cancer Research in HKUMed
6. Gastrointestinal